|
Market Cap (20-May) $2,216,115,200 (333rd) |
Close (30-Jun) $1.14 |
Volume (30-Jun) 2,606,681 |
Shortsold (5-May) 72,824,861 (5.70%) (40th) |
|
52w High $3.37 |
52w Low $0.88 |
P/E 454.55 |
EPS -0.14 |
MSB released this announcement to the ASX on 18 January 2022, 10:21. The announcement is not marked as price sensitive, and is 21 page(s) in length and 489.88kb in size.
You can view all announcements from MSB and see how they appear on a price chart on the announcements page.
At the date of this announcement, MSB was 9.536% short sold according to ASIC data. It was ranked the 7th most shorted stock on the ASX. It remains ranked 40th as of the latest reported data (05 May 2025).
| Other Recent Announcements from MSB | |
|---|---|
| Change of Director's Interest Notice | 13 June 2023, 8:56 |
| Mesoblast Director Appointed to Strategic Advisory Role | 5 June 2023, 9:41 |
| MSB Reports Q3 Financial Results and Operational Highlights | 26 May 2023, 8:32 |
| Cleansing Notice and Appendix 2A | 18 January 2022, 10:21 |
| Proposed issue of securities - MSB | 18 January 2022, 9:56 |
| Appendix 3G, Appendix 3H and Appendix 3Y | 17 January 2022, 18:02 |
| 36-Month Results of Phase 3 Trial in Chronic Low Back Pain | 12 January 2022, 10:05 |
You must be logged in to post a reply.
Mesoblast 